Business description
Formycon is a leading and independent developer of biosimilar drugs, meeting the highest quality standards, for marketing and distribution around the globe. The company spans the entire pharmaceutical value creation chain all the way through to phase III clinical trials and registration. Formycon specifically develops biosimilars to meet the stringent standards required for regulatory approval in the most highly regulated markets (EU, U.S., Japan, Canada, Australia), and positions itself as preferred partner for major pharmaceutical and generic corporations.
Management board & Supervisory board
| CEO |
| Stefan Glombitza |
| Management board |
| Enno Spillner, Nicola Mikulcik, Andreas Seidl |
| Supervisory board |
| Wolfgang Essler, Nicholas Haggar, Klaus Röhrig, Bodo Coldewey, Colin Bond |
Company data
| Name: |
Formycon AG |
| Address: |
Fraunhoferstraße 15,D-82152 Martinsried/Planegg |
| Phone: |
+49-89-864667-100 |
| Fax: |
+49-89-864667-110 |
| E-mail: |
info@formycon.com
|
| Internet: |
www.formycon.com |
| Industry: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Sub sector: |
Pharmaceuticals |
| End of financial year: |
12/31 |
| Free Float: |
36.20% |
| IPO date: |
12/20/2010 |